Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Res...
Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...
Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Ph...
But a game-changer occurred in 2013, when several researchers showed that a gene-editing tool called CRISPR could alter the DNA of human cells like a v...
The UniVy OsteoVy-Ti NanoVy-HA Cervical IBF System features VySpine's NanoVy-HA technology in partnership with Promimic AB. NanoVy-HA is a process in which...
Agilent Technologies Inc. (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with Theragen Bio in South Korea to boos...
Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report this very positive and important development for mdxhealth. The quality ...
Juntendo University, Sysmex Corporation, and ThinkCyte K.K. have announced a collaborative research partnership to advance the early detection and treatmen...
"Today's approval is an important advance in cell therapy treatment in patients with blood cancers," said Peter Marks, M.D., Ph.D., director of the FDA's C...
Bridging the gap between histopathology and molecular pathology Xyall and Indica Labs have entered into a global strategic partnership designed to bridge ...
Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...
Agena Bioscience and nRichDX have advanced their existing technical collaboration to a commercial partnership that co-promotes their products to researcher...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer ...
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences&rs...
© 2024 Biopharma Boardroom. All Rights Reserved.
